Merck to buy VC-backed Rigontec
Merck has agreed to acquire Germany-based Rigontec, which focuses on RIG-I targeting RNA therapeutics. According to terms of the deal, Merck will make an upfront cash payment of 115 million euros to Rigontec’s shareholders. Also, based on the fulfillment of certain milestones, Merck may make additional contingent payments of up to 349 million euros. Rigontec is backed by Boehringer Ingelheim Venture Fund, Forbion Capital Partners, High-Tech Gründerfonds, MP Healthcare Venture Management, NRW.BANK, Sunstone Capital and Wellington Partners Life Sciences.
6 September 2017•4 mins read
